In short
Clinical trials are investigating LTG-001 in people with osteoarthritis of the knee. This article explains what the studies aim to measure, including pain relief and safety, and who may take part. The trial data describe a phase 2 study comparing LTG-001 with placebo.
Key points
- Clinical trials are studying LTG-001 in people with osteoarthritis of the knee. The main trial is a Phase 2 interventional study with 180 planned participants. It compares LTG-001 with a matched placebo to see whether it helps reduce knee pain. The main measure is the change in WOMAC pain score over treatment periods. The study is authorised and is focused on both benefit and safety checks.
Trial overview
The available clinical trial is studying LTG-001 in people with osteoarthritis of the knee, a joint condition that can cause pain and stiffness.1 The study is designed to see whether LTG-001 can improve pain compared with placebo.1
This is an interventional study, which means researchers give a study treatment and then compare the results between groups.1 The trial is listed as Phase 2 and is currently authorised.1
Who can participate
The target population is people with osteoarthritis of the knee.1 The trial data do not give more detailed inclusion or exclusion rules, so the main known requirement is the condition being studied.1
In simple terms, this means the study is meant for adults or patients who already have knee osteoarthritis, but the exact age limits and other entry rules are not provided in the source data.1
Study design and treatment comparison
The study compares LTG-001 with a matched placebo, meaning a look-alike treatment used to make the comparison fair.1 The intervention list shows LTG-001 as a tablet taken by oral use, but the trial data should be read as study information rather than general treatment advice.1
The brief summary says the study aims to evaluate the efficacy of LTG-001 versus placebo for pain associated with knee osteoarthritis.1 Efficacy means how well a treatment works under study conditions.1
What is being measured
The main endpoint, or main result being measured, is the change in WOMAC pain subscale score from before treatment to the end of each treatment period.1 WOMAC is a patient-reported questionnaire used to measure pain and function in arthritis studies.1
The trial measures this score at multiple time points, including Day 1 and Day 28 at the start of each treatment period, and Day 14 and Day 41 at the end of each treatment period.1 This helps researchers see whether pain changes during the study periods.1
Trial status and size
The study is authorised, which means it has approval to proceed.1 The planned enrollment is 180 people, so the trial is designed to include a moderate number of participants.1
Because the trial is Phase 2, the study is still in an early-to-mid stage of testing rather than a final confirmation stage.1 The main focus is on whether LTG-001 can help with knee pain and how the results compare with placebo.1